These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30764035)

  • 1. Management of neuroendocrine tumors: current and future therapies.
    Öberg KE
    Expert Rev Endocrinol Metab; 2011 Jan; 6(1):49-62. PubMed ID: 30764035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of neuroendocrine tumours: current and future medical therapy options.
    Oberg KE
    Clin Oncol (R Coll Radiol); 2012 May; 24(4):282-93. PubMed ID: 21907552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal neuroendocrine tumors.
    Öberg KE
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii72-80. PubMed ID: 20943646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
    Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
    J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T; Lee L; Jensen RT
    Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Caplin ME
    Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
    Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
    Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.
    Di Giacinto P; Rota F; Rizza L; Campana D; Isidori A; Lania A; Lenzi A; Zuppi P; Baldelli R
    Int J Endocrinol; 2018; 2018():8126087. PubMed ID: 30057604
    [No Abstract]   [Full Text] [Related]  

  • 12. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expanding role of somatostatin analogs in the management of neuroendocrine tumors.
    Wolin EM
    Gastrointest Cancer Res; 2012 Sep; 5(5):161-8. PubMed ID: 23112884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours.
    Costa F; Gumz B
    Eur Endocrinol; 2014 Feb; 10(1):70-74. PubMed ID: 29872467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.